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Abstract
• Lowering low-density lipoprotein cholesterol (LDL-C) concentration in
the population has been a goal of researchers and clinicians to prevent
atherosclerotic cardiovascular disease (ASCVD).
• Controversy surrounds using [LDL-C] as the primary lipid biomarker to
evaluate the risk of cardiovascular events. An article search dating back
to 2005 of PubMed and The Cochran Library was conducted.
• The purpose of this investigation was to determine if LDL-C should be
the primary lipid biomarker used to determine ASCVD treatment and
prevention. This investigation researched other lipid biomarkers and
targets to determine clinical relevance and if the level of those markers
more accurately represents ASCVD in adults 21-75 years of age not
afflicted by other chronic diseases.
• It was found that both non-high-density lipoprotein cholesterol (nonHDL-C) and apolipoprotein B (apoB) both better represent ASCVD risk
than LDL-C, with apoB being superior to non-HDL-C.

Introduction
• ASCVD is the most common cause of death worldwide. In 2010,
ASCVD accounted for approximately 16 million deaths, 40% of deaths
in the developed world (Kasper et al., 2015).
• Researchers and clinicians divide their treatment strategies in to 2
categories; primary prevention and secondary prevention. Primary
prevention seeks to prevent new-onset ASCVD, while secondary
prevention extends to all other patients with already established
ASCVD.
• Lowering LDL-C levels to set target goals using statin drugs is the
standard treatment regime.
• Early in the 21st century researchers started to question if LDL-C was
actually the biomarker that best predicted ASCVD. ApoB and nonHDL-C were lipid biomarker that received much attention and
research.
• One ApoB molecule is attached to each VLDL, IDL, and LDL.
Measuring apoB directly measures the number of all 3 atherogenic lipid
particles. Its measurement requires fasting, a high cost, and is not
standardized.
• Non-HDL-C is calculated by subtracting HDL-C from total cholesterol.
Like apoB, non-HDL-C measurement is a way to determine combined
levels of VLDL, IDL, and LDL

Statement of the Problem
• With so many different lipid biomarkers used to evaluate ASCVD risk,
and multiple treatment and prevention guidelines available, it is
challenging for a primary care provider to select the most efficacious
and cost-effective treatment plan.

Research Questions
• What are the current guidelines for ASCVD treatment and prevention in
adults 21-75 years of age?
• In the rural primary care setting, where state-of-the-art laboratory
equipment is unavailable, the use of which lipid biomarker is most
efficacious in assessing ASCVD risk in male and female adults 21-75
years of age?

Literature Review

Applicability to Clinical
Practice

Lipid Guidelines
• In 2013 guidelines by the American College of Cardiology and
American Heart Association, by Stone et al. (2013) were released.
These guidelines brought about a departure from the previous
guidelines, eliminating goals for LDL-C. Instead of LDL-C therapeutic
goals, on the basis of a large consistent body of evidence, 4 major statin
benefit groups were identified for whom the ASCVD risk reduction
clearly outweighs the risk of adverse events.
1) Secondary prevention in individuals with clinical ASCVD
2) Primary prevention in individuals with primary elevations of LDL-C
≥ 190 mg/dL
3) Primary prevention in individuals with diabetes 40-75 years of age
who have LDL-C 70-189 mg/dL,
4) Primary prevention in individuals without diabetes and with
estimated 10-year ASCVD risk ≥ 7.5%, 40 to 75 years of age with
LDL-C 70-189 mg/dL (Stone et al., 2013).
• Two other prominent guidelines, from the International Atherosclerosis
Society (IAS) and the National Lipid Association (NLA), each use LDL-C
concentration levels to determine successful pharmacological
prevention of ASCVD. However, because evidence shows that VLDL is
atherogenic like LDL, both guidelines also contain an additionally
recommended goal for Non-HDL-C.

Lipid Guidelines
• Treatment goals suggested by the NLA and IAS facilitate effective
communication between the patient and clinician
• Treatment goals provide an easily understandable means to discuss
progress towards effective therapy. This will maximize long-term
adherence by the patient to the treatment strategy.
Lipid Biomarkers
• Non-HDL-C is the most efficacious lipid biomarker to assess risk of
ASCVD and to evaluate successful treatment in rural primary care
medicine.
• Non-HDL-C simplifies results for both the clinician and the patient, is
universally available, has low cost, does not requires fasting, and has
been proven by research to be efficacious.
• Non-HDL-C does not require addition laboratory equipment or studies
besides the already standardized lipid panel. Non-HDL-C testing is
simpler, calculated as the difference of 2 stable and easily measured
parameters, total cholesterol and HDL-C.

References

Lipoprotein Physiology
• Plasma lipoproteins are divided into five major classes based on their
relative density: chylomicrons, very-low-density lipoproteins (VLDLs),
intermediate-density lipoproteins (IDLs), low-density lipoproteins
(LDLs), and high-density lipoproteins (HDLs).
Lipid Biomarkers
• LDL-C has been the mainstay biomarker and pharmacologic target to
prevent ASCVD. However, new research has provided evidence that
other lipid biomarkers better represent the risk of developing ASCVD.
• A meta-analysis conducted by Boekholdt et al. (2012) compared lipid
biomarker levels in patients treated with statin medications with risk of
cardiovascular events. The adjusted hazard ratios (HRs) for major CV
events per 1-SD increase were 1.13 (95% CI 1.10-1.17) for LDL-C, 1.16
(95% CI 1.12-1.19) for non-HDL-C, and 1.14 (95% CI 1.11-1.18) for
apoB. These HRs were significantly higher for non-HDL-C that LDL-C
(P=0.002) and apoB (P=0.02). This data led the authors to conclude
“that among statin treated patients, non-HDL-C had a stronger
association with risk of major cardiovascular events than LDL-C and
apolipoprotein B” (Boekholdt et al., 2012, p. 1307).
• A case-control study by Pischon et al. (2005), compared apoB, non–
HDL-C, LDL-C, and other lipid markers as predictors of coronary heart
disease. After adjustment for matching factors, the relative risk of CHD
in the highest quintile compared with the lowest quintile was 2.76
(95% confidence interval [CI], 1.66 to 4.58) for non–HDL-C, 3.01 (95%
CI, 1.81 to 5.00) for apoB, 1.81 (95% CI, 1.12 to 2.93) for LDL-C, 0.31
(95% CI, 0.18 to 0.52) for HDL-C, 2.41 (95% CI, 1.43 to 4.07). The
authors concluded “that non–HDL-C was more strongly correlated with
CHD than LDL-C”, but that “apoB showed the strongest association
with risk of CHD” and “apoB was associated with increased risk of
CHD even after adjustment for LDL-C or non–HDL-C” (Pischon et al.,
2005).
• Sniderman et al. (2011) attempted to identify all “published
epidemiological studies that contained estimates of the relative risks of
non-HDL-C and apoB of fatal or nonfatal ischemic cardiovascular
events” (p. 338). The authors reported that apoB was the most potent
marker of cardiovascular risk (RRR, 1.43; 95% CI, 1.35 to 1.51), LDL-C
was the least (RRR, 1.25; 95% CI, 1.18 to 1.33), and non-HDL-C was
intermediate (RRR, 1.34; 95% CI, 1.24 to 1.44).

Discussion
Treatment Goals
• The ACC/AHA Guideline on the Treatment of Blood Cholesterol to
Reduce Atherosclerotic Cardiovascular Risk in Adults, by Stone et al.
(2013), is one of the most widely used guideline by clinicians in the
U.S. The most recent report published in 2013 brought about
departure from past reports and a different approach than guidelines
from other cardiovascular associations. These guidelines were the first
to exclude treatment goals for LDL-C. Rather than using the
concentration of lipids in the blood as a treatment goal, the ACC/AHA
guidelines use the intensity of statin therapy as the goal of treatment.
• These new guidelines, and the absence of cholesterol targets, started a
debate amongst clinicians and researchers. Guidelines by the
International Atherosclerosis Society (Expert Dyslipidemia Panel of the
International Atherosclerosis Society Panel members, 2014), the
National Lipid Association (Jacobson et al., 2015), and previous ATP
guidelines all included LDL-C treatment goals.
Lipid Biomarkers
• Up until recently all the attention has been paid to LDL-C, so-called
‘bad cholesterol’. All previous guidelines used the concentration of
LDL-C in the blood to determine the type of intervention and assess for
successful treatment. LDL-C is now firmly entrenched in the minds of
patients and clinicians alike as the primary marker for cardiovascular
health.
• Boekholdt et al. (2012) found that non-HDL-C is more strongly
associated with cardiovascular events than LDL-C and apoB.
• Research by Pischon et al. (2005) and Sniderman et al. (2011) found
that apoB was the superior lipid biomarker, but that non-HDL-C was
also more strongly correlated with CHD that LDL-C.
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